Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR29022841

— · C

50993a7e-d9d7-5399-b802-b61066adcaf0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.490
  • E2F_TARGETS+0.450
  • MTORC1_SIGNALING+0.430
  • MYC_TARGETS_V1+0.420
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
  • GLYCOLYSIS+0.350
  • PANCREAS_BETA_CELLS+0.350
  • CHOLESTEROL_HOMEOSTASIS+0.310
  • ESTROGEN_RESPONSE_EARLY+0.280
  • G2M_CHECKPOINT+0.280

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.280
  • IL6_JAK_STAT3_SIGNALING-0.260
  • WNT_BETA_CATENIN_SIGNALING-0.260
  • UV_RESPONSE_DN-0.240
  • ALLOGRAFT_REJECTION-0.230
  • TNFA_SIGNALING_VIA_NFKB-0.230
  • IL2_STAT5_SIGNALING-0.150
  • KRAS_SIGNALING_UP-0.150
  • MITOTIC_SPINDLE-0.140
  • INTERFERON_GAMMA_RESPONSE-0.130

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-77-7140-01A-41R-2045-07
lung-landscapes@6
—cohortSQ20.780
2SRR8518397
breast-umap@18
—E0.773
3MNG432
mng-umap@100
——0.768
4TCGA-E9-A1RB-01A-11R-A157-07
breast-umap@18
—C0.763
5SRR8942949
bladder-landscape@3
——0.747
6BS_JZRM1S3T
medullo-epn-umap@date-based
MedMedulloblastoma0.743
7C3N-03204
lung-landscapes@6
—cohortSQ20.739
8TCGA-50-5072-01A-21R-1858-07
lung-landscapes@6
—cohortA40.738
9MDT-AP-0426
medullo-epn-umap@date-based
MedMedulloblastoma0.734
10BSR_12_0070_A1_S79
breast-umap@18
—C0.733

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.490Idelalisib— uncovered
E2F_TARGETS0.450Inavolisib— uncovered
MTORC1_SIGNALING0.430Inavolisib— uncovered
MYC_TARGETS_V10.420Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.360Inavolisib— uncovered
GLYCOLYSIS0.350Inavolisib— uncovered
PANCREAS_BETA_CELLS0.350Cobimetinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.310Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.280Inavolisib— uncovered
G2M_CHECKPOINT0.280Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.260Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.250Remibrutinib— uncovered
PROTEIN_SECRETION0.230Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered
DNA_REPAIR0.140Idelalisib— uncovered
COAGULATION0.120Binimetinib— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
HYPOXIA0.100Idelalisib— uncovered
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered
SPERMATOGENESIS0.090Inavolisib— uncovered